The Recall Desk
SevereFDA (Devices)·Z-1009-2022·Announced 2022-05-18

FDA Recalls Accula SARS-CoV-2 Test for False Positive Risk

Mesa Biotech is recalling approximately 6,162 units of the Accula SARS-CoV-2 Test due to an increased risk of false positive results, which could delay correct diagnosis and treatment.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: FDA Class I classification requires a minimum severity score of 4 per the rubric. Although no illnesses or injuries are reported, the potential for false positive test results in a diagnostic device represents a significant defect affecting diagnostic accuracy and patient care.

Plain-English summary

The Accula SARS-CoV-2 Test (REF: COV4100), manufactured by Mesa Biotech, Inc., is being recalled due to an increased potential for false positive results. Approximately 6,162 units were distributed across the United States in multiple states.

False positive test results occur when a test incorrectly indicates the presence of an infection that is not actually present. This increases the risk that patients could be incorrectly diagnosed and may experience delays in receiving the correct diagnosis and treatment.

The FDA classified this as a Class I recall.

The recalled product

Product
Accula SARS-CoV-2 Test, REF: COV4100
Manufacturer
MESA BIOTECH, INC
Hazard
  • false-positive
  • diagnostic-error

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (20)

  • UDI/DI: B540COV41000
  • P22006-026
  • P22010-021
  • P22024-023
  • P22024-030
  • P22026-006
  • P22026-012
  • P22026-016
  • P22010-001
  • P22010-030
  • P22024-026
  • P22024-032
  • P22026-007
  • P22026-013
  • P22026-017
  • P22010-017
  • P22010-032
  • P22024-027
  • P22026-002
  • P22026-008

Distribution

Distributed nationwide across the United States.